Theravance Biopharma, Inc. (NASDAQ:TBPH) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.theravance.com
Earnings Expectation
Theravance Biopharma, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, TBPH is expected to report 3Q20 loss of $ 0.97 per share from revenue of $ 18.57 million.
For the full year, analysts anticipate top line of $ 81.60 million, while looking forward to loss of $ 4.07 per share bottom line.
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders.
